PHILADELPHIA and VANCOUVER, British Columbia, Aug. 5, 2026
BriaCell Therapeutics Corp. has received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for Bria-PROS+, allowing the company to initiate a Phase 1/2a clinical study evaluating its next-generation personalized, off-the-shelf cell-based immunotherapy for prostate cancer. The FDA’s Study May Proceed letter marks a significant regulatory milestone for the company as it expands its immuno-oncology pipeline beyond breast cancer. Bria-PROS+ is designed to incorporate additional immune-activating components aimed at enhancing anti-tumor activity while maintaining a favorable safety profile. The program also previously secured a $2 million non-dilutive grant from the U.S. National Cancer Institute (NCI) to support manufacturing and clinical development, reinforcing confidence in the platform’s scientific potential.
BriaCell Advances Next-Generation Personalized Immunotherapy
According to Dr. William V. Williams, President and CEO of BriaCell, the FDA clearance represents an important advancement in the company’s strategy to develop innovative cancer immunotherapies for patients with limited treatment options. Bria-PROS+ has been engineered to stimulate multiple arms of the immune system, with the goal of generating a stronger and more durable anti-cancer response than conventional approaches. Unlike traditional therapies, the personalized platform is designed to activate both adaptive and innate immune responses, potentially improving efficacy while reducing the likelihood of immune escape. The initiation of the Phase 1/2a clinical study will enable BriaCell to evaluate the treatment’s safety, tolerability, and preliminary anti-tumor activity in patients with advanced prostate cancer.
Preclinical Data Demonstrated Broad Immune Activation
BriaCell reported that preclinical findings, previously presented at the American Association for Cancer Research (AACR) Annual Meeting, demonstrated that Bria-PROS+ successfully activated naïve T-cells, dendritic cells, and natural killer (NK) cells, indicating broad stimulation of both the adaptive and innate immune systems. This multi-targeted immune activation strategy is intended to improve tumor recognition and strengthen long-term immune responses against prostate cancer. The company believes that engaging multiple immune pathways could enhance clinical outcomes while helping prevent resistance mechanisms that frequently limit the effectiveness of existing cancer therapies. These encouraging laboratory findings provided the scientific rationale supporting advancement into human clinical trials following FDA authorization.
Advertisement
BriaCell Strengthens Expanding Immuno-Oncology Pipeline
The Bria-PROS+ program further expands BriaCell’s growing portfolio of personalized cancer immunotherapies. The company is currently conducting a Phase 3 pivotal trial for its Bria-IMT™ program in metastatic breast cancer while also advancing Bria-OTS™ and Bria-BRES+™, the latter having recently received FDA clearance for clinical evaluation in breast cancer. BriaCell’s personalized treatment platform utilizes human leukocyte antigen (HLA) matching between patients and therapeutic cell lines to optimize immune responses. With the latest FDA clearance, the company continues to broaden the application of its proprietary immunotherapy technology across multiple solid tumors, positioning Bria-PROS+ as a promising investigational treatment candidate for prostate cancer and reinforcing its long-term strategy of developing innovative cell-based immunotherapies for patients with significant unmet medical needs.
Source: BriaCell Therapeutics press release
